This Article Full Text Full Text (PDF) All Versions of this Article: 20/7/1506    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carascossa, S. Articles by Jalaguier, S. Search for Related Content PubMed PubMed Citation Articles by Carascossa, S. Articles by Jalaguier, S.

Receptor-Interacting Protein 140 Is a Repressor of the Androgen Receptor Activity

Institut National de la Santé et de la Recherche Médicale (S.C., J.G., V.G., A.L., E.B., A.C., J.-C.N., V.C., S.J.), Unité 540, Montpellier F-34090, France; and Institute of Reproductive and Developmental Biology (R.W.), Imperial College London, London W12 0NN, United Kingdom

Address all correspondence and requests for reprints to: Stéphan Jalaguier, Institut National de la Santé et de la Recherche Médicale, Unité 540, 60 rue de Navacelles, F-34090 Montpellier, France. E-mail: jalaguie{at}montp.inserm.fr.

The androgen receptor (AR) is a ligand-activated transcription factor that controls growth and survival of prostate cancer cells. In the present study, we investigated the regulation of AR activity by the receptor-interacting protein 140 (RIP140). We first showed that RIP140 could be coimmunoprecipitated with the receptor when coexpressed in 293T cells. This interaction appeared physiologically relevant because chromatin immunoprecipitation assays revealed that, under R1881 treatment, RIP140 could be recruited to the prostate-specific antigen encoding gene in LNCaP cells. In vitro glutathione S-transferase pull-down assays provided evidence that the carboxy-terminal domain of AR could interact with different regions of RIP140. By means of fluorescent proteins, we demonstrated that ligand-activated AR was not only able to translocate to the nucleus but also to relocate RIP140 from very structured nuclear foci to a diffuse pattern. Overexpression of RIP140 strongly repressed AR-dependent transactivation by preferentially targeting the ligand binding domain-dependent activity. Moreover, disruption of RIP140 expression induced AR overactivation, thus revealing RIP140 as a strong AR repressor. We analyzed its mechanism of transrepression and first demonstrated that different regions of RIP140 could mediate AR-dependent repression. We then showed that the carboxy-terminal end of RIP140 could reverse transcriptional intermediary factor 2-dependent overactivation of AR. The use of mutants of RIP140 allowed us to suggest that C-terminal binding protein played no role in RIP140-dependent inhibition of AR activity, whereas histone deacetylases partly regulated that transrepression. Finally, we provided evidence for a stimulation of RIP140 mRNA expression in LNCaP cells under androgen treatment, further emphasizing the role of RIP140 in androgen signaling.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR

Coregulators:   RIP140  |  GRIP1

Ligands:   Bicalutamide  |  R1881

This article has been cited by other articles:

				H. V. Heemers and D. J. Tindall Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex Endocr. Rev., December 1, 2007; 28(7): 778 - 808. [Abstract] [Full Text] [PDF]